Similarities and Differences in Tumor Growth, Skeletal Remodeling and Pain in an Osteolytic and Osteoblastic Model of Bone Cancer

@article{Halvorson2006SimilaritiesAD,
  title={Similarities and Differences in Tumor Growth, Skeletal Remodeling and Pain in an Osteolytic and Osteoblastic Model of Bone Cancer},
  author={Kyle G. Halvorson and Molly A. Sevcik and Joseph R. Ghilardi and Thomas J. Rosol and Patrick W Mantyh},
  journal={The Clinical Journal of Pain},
  year={2006},
  volume={22},
  pages={587-600}
}
More than 1.3 million cases of cancer will be diagnosed in 2006 in the United States alone, and 90% of patients with advanced cancer will experience significant, life-altering cancer-induced pain. Bone cancer pain is the most common pain in patients with advanced cancer as most common tumors including breast, prostate, and lung have a remarkable affinity to metastasize to bone. Once tumors metastasize to bone they are a major cause of morbidity and mortality as the tumor induces significant… Expand
Bone cancer pain
TLDR
If successful, several mechanism‐based therapies have the potential to significantly enlarge the repertoire of modalities that can be used to treat bone cancer pain and improve the quality of life, functional status, and survival of patients with bone cancer. Expand
A micro-imaging study linking bone cancer pain with tumor growth and bone resorption in a rat model
TLDR
The imaging approach allowed us to consistently detect the tumor before the onset of pain, paving the way for the preemptive identification of at-risk patients and improving the understanding of the events leading to tumor-induced bone pain. Expand
Animal Models of Bone Metastasis
TLDR
This review provides an overview of the current in vivo animal models used in the study of skeletal metastases or local tumor invasion into bone and focuses on mammary and prostate cancer, lymphoma, multiple myeloma, head and neck squamous cell carcinoma, and miscellaneous tumors that metastasize to bone. Expand
Role of the Bone Microenvironment in the Development of Painful Complications of Skeletal Metastases
TLDR
Cancer-induced bone pain is a complex and challenging condition that currently has no standard effective treatments other than opioids and further studies are clearly warranted to better understand this painful condition and develop more effective and safer targeted therapies. Expand
The critical role of the bone microenvironment in cancer metastases
TLDR
Tumor growth can be effectively inhibited by targeting the bone and its microenvironment rather than the tumor itself alone, which supports a novel paradigm. Expand
Development of imaging probes for bone cancer in animal models. A systematic review.
TLDR
The advantages and disadvantages of the currently available imaging techniques that aim at identifying bone tumors are described, as well as an update on the animal models applicable at mimicking bone tumor characteristics. Expand
Osteosarcoma and Metastasis Associated Bone Degradation—A Tale of Osteoclast and Malignant Cell Cooperativity
TLDR
A model for cancer-associated bone degradation is proposed that involves a collaboration between osteoclasts and cancer cells and in which both cell types may directly participate in the degradation process. Expand
Cannabinoid Receptor 2: A Novel Multi-Targeted Approach in the Treatment of Breast Cancer and Related Skeletal Metastasis
TLDR
It is shown that the CB2 specific agonist JWH-015 mediates inflammatory factors in vitro and in vivo in the femoral intramedullary cavity in a tumor microenvironment via effects specific to the tumor cells. Expand
Bone Cancer Pain, Mechanism and Treatment
TLDR
CIBP is a unique type of pain with neuropathic and nociceptive components, treated by a range of NSAIDs to strong opioids, but remains undertreated in one-third of cases. Expand
Skeletal metastases: Decreasing tumor burden by targeting the bone microenvironment
TLDR
The results suggest a novel paradigm in which tumor growth can be effectively inhibited by drugs that target cells in the bone microenvironment and not the tumor cells themselves. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 131 REFERENCES
Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis
TLDR
It is emphasized that it is essential to utilize a model where pain, skeletal remodeling and tumor growth can be simultaneously assessed, as each of these can significantly impact patient quality of life and survival. Expand
Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2.
TLDR
It is suggested that chronic administration of a COX-2 inhibitor blocks prostaglandin synthesis at multiple sites, and may have significant clinical utility in the management of bone cancer and bone cancer pain. Expand
Osteoprotegerin diminishes advanced bone cancer pain.
TLDR
Results indicated that osteoprotegerin treatment halted further bone destruction, reduced ongoing and movement-evoked pain, and reversed several aspects of the neurochemical reorganization of the spinal cord. Expand
Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
TLDR
It is demonstrated that excessive tumor-induced bone destruction is involved in the generation of bone cancer pain and that osteoprotegerin may provide an effective treatment for this common human condition. Expand
A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone.
TLDR
The present results suggest that anti-NGF therapy may be effective in reducing pain and enhancing the quality of life in patients with prostate tumor-induced bone cancer pain. Expand
Analgesic efficacy of bradykinin B1 antagonists in a murine bone cancer pain model.
TLDR
It is demonstrated that pharmacologic blockade of the bradykinin B1 receptor is effective in reducing bone cancer pain-related behaviors, suggesting that B1 antagonists might be useful in attenuating bone cancerPain in humans. Expand
Skeletal complications of malignancy
TLDR
Good prognostic factors for survival after the development of bone metastases are good histologic grade, positive estrogen receptor status, bone disease at initial presentation, a long disease free interval, and increasing age, while patients with disease that remains confined to the skeleton have a better prognosis than those with subsequent visceral involvement. Expand
Malignant bone pain: pathophysiology and treatment
TLDR
The use of analgesics according to the WHO ladder is recommended and non‐steroidal anti‐inflammatory drugs (NSAIDs) have a specific efficacy in malignant bone pain. Expand
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
TLDR
It is demonstrated that risedronate decreases metastatic MDA-231 breast cancer burden selectively in bone, as well as suppresses progression of established osteolytic lesions and prevents the development of new osteolytics lesions; thus, the data suggest that inhibition of osteoclastic bone resorption may be a useful adjunctive therapy for the treatment of cancers that have colonized in bone. Expand
Endothelin and the tumorigenic component of bone cancer pain
TLDR
It is shown that in a murine osteolytic 2472 sarcoma model of bone cancer pain, the 2472 Sarcoma cells express high levels of ET-1, but express low or undetectable levels of endothelin A (ETAR) or B (ETBR) receptors whereas a subpopulation of sensory neurons express the ETAR and non-myelinating Schwann cells express theETBR. Expand
...
1
2
3
4
5
...